Inclination toward Multidisciplinary Approach for Nephropathic Cystinosis Treatment
For several decades, researchers, healthcare providers, drug developers, and other participants of the healthcare systems worldwide continue to develop new treatments and drugs for patients suffering from rare and chronic diseases that are complex in nature. A similar trend can be observed within the nephropathic cystinosis treatment market, as continual research and clinical trials bring forward new potential treatments and medications. At present, improving the overall quality of patient care suffering from nephropathic cystinosis remains the key area of focus for companies involved in the current market for nephropathic cystinosis.
Healthcare providers are increasingly inclined toward adopting the multidisciplinary approach for patients suffering from nephropathic cystinosis, which predominantly includes psychologists, nurses, physicians, social workers, and nutritionists. Over the past three decades, long-term prognosis for patients suffering from cystinosis has improved at a rapid pace due to the availability of cysteine-depleting drug cysteamine and notable advancements in kidney transplantation techniques. The advent of cysteamine for the treatment of nephropathic cystinosis has also played a key role in addressing the complications associated with extra-renal diseases. The treatment of nephropathic cystinosis varies in the developing and developed regions of the world. However, with growing investments and promising outcome from research, healthcare providers around the world are increasingly providing effective and optimum nephropathic cystinosis treatments. At the back of these factors the global nephropathic cystinosis treatment market is expected to attain a market value of ~US$ 263 Mn by the end of 2027.
To know the scope of our report Get a Sample on Nephropathic Cystinosis Treatment Market
Advancements and Innovations in Monitoring of Nephropathic Cystinosis Treatment to Boost Market Growth
Cystinosis is deemed as a rare inheritable multisystem storage disease, and can be characterized by lysosomal cysteine accumulation and other crystal formation in the different tissues within the body. Due to the narrow therapeutic window, cysteamine treatment needs to be monitored closely. Conventional treatment monitoring techniques have proved to be impractical, complex, and require specialized laboratories. Participants operating in the current nephropathic cystinosis treatment market are currently focusing on the development of innovative strategies that are likely to streamline the monitoring of cystinosis. As per recent developments in this regard, macrophages are anticipated to play a key role in pathogenesis of cystinosis. Innovations and advancements in the monitoring of nephropathic cystinosis treatment are expected to come at a consistent pace during the forecast period due to which, the market for nephropathic cystinosis is expected to witness a considerable growth in the coming years.
Get a glimpse of the in-depth analysis through our Report Brochure
Market Participants Continue to Place Trust in Systematic Depletion Therapy
Within the nephropathic cystinosis treatment market, systematic depletion therapy and symptomatic therapy are the two main types of treatment. The adoption of systematic depletion therapy is expected to remain considerably higher than that of symptomatic therapy, as it has emerged as an ideal treatment type in the removal of cysteine from lysosomes, thereby preventing any sort of complications. Several short-term studies have also revealed that systematic depletion therapy have shown promising results in maintaining the growth rate and improving renal function stabilization. Moreover, as systematic depletion therapy leads to the reduction of intralisossomal cysteine and cysteamine stocks, prognosis improvement in these patients can be observed.
Companies Aim to Attain FDA Approval for New Products to Gain Advantage
Receiving the approval from the FDA is one of the most critical phases in the development of new treatment and drugs. Several companies operating in the nephropathic cystinosis treatment market are increasingly focusing on receiving the FDA approval for their products. For instance, in July 2019, Horizon Therapeutics announced that the company has received the green signal from the U.S. Food and Drug Administration for the development of PROCYSBI Delayed-release Oral Granules in Packets. While companies continue to launch new drugs for nephropathic cystinosis treatment and seek FDA approval for the same, several drugs in the pipeline are expected to enter the nephropathic cystinosis market in the coming years. Therapy and renal replacement will continue to provide optimum care for patients suffering from nephropathic cystinosis.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
The global nephropathic cystinosis treatment market is expected to grow at a modest CAGR of ~2% during the forecast period. The market growth can be largely attributed to a range of factors, including soaring investments for research & development activities, advent of patient assistance, product approval from the FDA, and increasing awareness among individuals pertaining to the effectiveness of nephropathic cystinosis treatments. Companies operating in the current market landscape should ideally focus on the development of new drugs and treatment, and align their growth strategies in-sync with the current trends, regulatory guidelines, and more to gain an edge in the current nephropathic cystinosis treatment market.
Nephropathic Cystinosis Treatment Market: Overview
- Nephropathic cystinosis is a rare form of disease. It is an inherited (autosomal recessive) lysosomal storage disorder caused by defective transport of the amino acid cystine out of lysosomes. The stored cystine is poorly soluble and crystallizes within the lysosomes of many cell types, leading to widespread tissue and organ damage.
- Nephropathic cystinosis treatment comprises cysteamine depletion therapy with symptomatic treatment for the disease. At a severe stage, renal transplantation option is adopted.
- Systemic depletion therapy by cysteamine is the most common and only effective option for direct effect on nephropathic cystinosis treatment
- Moreover, symptomatic therapy is provided to cure major symptoms such as electrolytes in Fanconi syndrome in children and Indomethacin in water losses in patients with nephropathic cystinosis
- Renal transplantation is usually required in patients with nephropathic cystinosis who are diagnosed late and do not begin cysteamine treatment at an early age, even patients who start cysteamine at an early age may eventually require transplantation. This may be because patients find it impossible to continue taking Cystagon four times a day at six-hour intervals for their entire lives.
- Increase in public and private initiatives in funding for research & treatment of cystinosis is the major driving factor responsible for the growth of the global nephropathic cystinosis treatment market
- For instance, in 2018, CRF awarded 16 new grants totaling US$ 2.8 Mn for cystinosis research and it funded 10 research grants in 2019 which totaled US$ 2.6 Mn
- Emergence of patient assistance and helping hand programs for nephropathic cystinosis patients and rise in awareness regarding nephropathic cystinosis among people through various programs are some of the major factors responsible for the growth of the global nephropathic cystinosis treatment market
- Moreover, product approval by regulatory bodies and dosage form modification for better patient compliance are also fueling the growth of the global nephropathic cystinosis treatment market
Market Segmentation: Nephropathic Cystinosis Treatment Market
- Based on treatment type, the global nephropathic cystinosis treatment market has been bifurcated into therapy and renal transplantation
- Therapy is further sub-segmented into systemic depletion therapy and symptomatic therapy
- In terms of sales channel, the global nephropathic cystinosis treatment market has been divided into hospitals, specialty/retail pharmacies, and others
- Each of the nephropathic cystinosis treatment market segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights
- The nephropathic cystinosis treatment market report provides current and future revenues (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027 along with market size estimations.
Regional Overview: Nephropathic Cystinosis Treatment Market
- In terms of region, the global nephropathic cystinosis treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
- North America is anticipated to be a highly lucrative market for the nephropathic cystinosis during the forecast period and dominated the market in 2018
- The current and future nephropathic cystinosis treatment market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027
- The study also offers a list of recommendations, highlights, and useful insights of the market which will help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process
Major Players
- The nephropathic cystinosis treatment market report concludes with the company profiles section that includes key information about the major players in the market
- Key players analyzed in nephropathic cystinosis treatment market report are
- Horizon Therapeutics plc
- Mylan N.V.
- Chiesi Farmaceutici SpA
- Recordati Rare Diseases
- AVROBIO, Inc.
- Leadiant Biosciences, Inc.
- Eloxx Pharmaceuticals
- GlaxoSmithKline plc.
- Each of these players has been profiled in the global nephropathic cystinosis treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Nephropathic Cystinosis Treatment Market – Segmentation
TMR’s study on the global nephropathic cystinosis treatment market includes information divided into three sections ? treatment type, sales channel, and region. Changing industry trends and other crucial market dynamics associated with these sections of the global nephropathic cystinosis treatment market have been discussed in detail.
|
Treatment Type |
Therapy
Renal Transplantation |
|
Sales Channel |
Hospitals Specialty/Retail Pharmacies Others |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Frequently Asked Questions
What is the total market worth of nephropathic cystinosis treatment market?
The global nephropathic cystinosis treatment market was worth US$ 215 Mn and is projected to reach a value of US$ 263 Mn by the end of 2027
What is the anticipated CAGR of the nephropathic cystinosis treatment market in the forecast period?
Nephropathic cystinosis treatment market is anticipated to grow at a CAGR of 2% during the forecast period
Which region is expected to project the highest market share in the global nephropathic cystinosis treatment market?
North America accounted for a major share of the global nephropathic cystinosis treatment market
What are the key driving factors for the growth of the nephropathic cystinosis treatment market?
Nephropathic cystinosis treatment market is driven by increase in public and private initiatives in funding for research & treatment of cystinosis is the major driving factor responsible for the growth of the global market
Who are the key players in the global nephropathic cystinosis treatment market?
Key players in the global nephropathic cystinosis treatment market include Horizon Therapeutics plc, Mylan N.V., Chiesi Farmaceutici SpA, Recordati Rare Diseases, AVROBIO, Inc., Leadiant Biosciences, Inc., Eloxx Pharmaceuticals, and GlaxoSmithKline plc
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Nephropathic Cystinosis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Nephropathic Cystinosis Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. 5.1.Regulatory Scenario by Region/globally
5.2. 5.2.Pipeline Analysis
5.3. 5.3.Nephropathic Cystinosis Epidemiology: Overview
6. Global Nephropathic Cystinosis Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2027
6.3.1. Therapy
6.3.1.1. Systemic Depletion Therapy
6.3.1.2. Symptomatic Therapy
6.3.2. Renal Transplantation
6.4. Market Attractiveness, by Treatment Type, 2019–2027
7. Global Nephropathic Cystinosis Treatment Market Analysis and Forecast, by Sales Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Sales Channel, 2017–2027
7.3.1. Hospitals
7.3.2. Specialty/Retail Pharmacies
7.3.3. Others
7.4. Market Attractiveness, by Sales Channel, 2019–2027
8. Global Nephropathic Cystinosis Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region, 2019–2027
9. North America Nephropathic Cystinosis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2017–2027
9.2.1. Therapy
9.2.1.1. Systemic Depletion Therapy
9.2.1.2. Symptomatic Therapy
9.2.2. Renal Transplantation
9.3. Market Value Forecast, by Sales Channel, 2017–2027
9.3.1. Hospitals
9.3.2. Specialty/Retail Pharmacies
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis, 2019–2027
9.5.1. By Treatment Type
9.5.2. By Sales Channel
9.5.3. By Country
10. Europe Nephropathic Cystinosis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2027
10.2.1. Therapy
10.2.1.1. Systemic Depletion Therapy
10.2.1.2. Symptomatic Therapy
10.2.2. Renal Transplantation
10.3. Market Value Forecast, by Sales Channel, 2017–2027
10.3.1. Hospitals
10.3.2. Specialty/Retail Pharmacies
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis, 2019–2027
10.5.1. By Treatment Type
10.5.2. By Sales Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Nephropathic Cystinosis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2027
11.2.1. Therapy
11.2.1.1. Systemic Depletion Therapy
11.2.1.2. Symptomatic Therapy
11.2.2. Renal Transplantation
11.3. Market Value Forecast, by Sales Channel, 2017–2027
11.3.1. Hospitals
11.3.2. Specialty/Retail Pharmacies
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis, 2019–2027
11.5.1. By Treatment Type
11.5.2. By Sales Channel
11.5.3. By Country/Sub-region
12. Latin America Nephropathic Cystinosis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2027
12.2.1. Therapy
12.2.1.1. Systemic Depletion Therapy
12.2.1.2. Symptomatic Therapy
12.2.2. Renal Transplantation
12.3. Market Value Forecast, by Sales Channel, 2017–2027
12.3.1. Hospitals
12.3.2. Specialty/Retail Pharmacies
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis, 2019–2027
12.5.1. By Treatment Type
12.5.2. By Sales Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Nephropathic Cystinosis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2027
13.2.1. Therapy
13.2.1.1. Systemic Depletion Therapy
13.2.1.2. Symptomatic Therapy
13.2.2. Renal Transplantation
13.3. Market Value Forecast, by Sales Channel, 2017–2027
13.3.1. Hospitals
13.3.2. Specialty/Retail Pharmacies
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis, 2019–2027
13.5.1. By Treatment Type
13.5.2. By Sales Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share/Position Analysis, by Company (2018)
14.3. Company Profiles
14.3.1. Horizon Therapeutics plc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Mylan N.V.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Chiesi Farmaceutici SpA
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Recordati Rare Diseases
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. AVROBIO, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Leadiant Biosciences, Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Eloxx Pharmaceuticals
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. GlaxoSmithKline plc
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis- Nephropathic Cystinosis
Table 02: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 03: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027
Table 04: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
Table 05: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 06: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 07: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 08: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027
Table 09: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
Table 10: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 11: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 12: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027
Table 13: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
Table 14: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 16: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027
Table 17: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
Table 18: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 20: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027
Table 21: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
Table 22: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 23: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 24: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027
Table 25: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
List of Figures
Figure 01: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 02: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 03: Global Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018
Figure 04: Global Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018
Figure 05: Global Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018
Figure 06: Global Nephropathic Cystinosis Treatment Market Value Share, by Region, 2018
Figure 07: Regulatory Approval Process - U.S.
Figure 08: Regulatory Approval Process - Europe
Figure 09: Regulatory Approval Process - Japan
Figure 10: Global Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 11: Global Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027
Figure 12: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Therapy, 2017-2027
Figure 13: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Renal Replacement, 2017-2027
Figure 14: Global Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 15: Global Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027
Figure 16: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027
Figure 17: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty/Retail Pharmacies, 2017–2027
Figure 18: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 19: Global Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027
Figure 20: Global Nephropathic Cystinosis Treatment Market Value Share, by Region, 2018 and 2027
Figure 21: Global Nephropathic Cystinosis Treatment Market Attractiveness, by Region, 2019–2027
Figure 22: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 23: North America Nephropathic Cystinosis Treatment Market Value Share, by Country, 2018 and 2027
Figure 24: North America Nephropathic Cystinosis Treatment Market Attractiveness, by Country, 2019–2027
Figure 25: North America Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 26: North America Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027
Figure 27: North America Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 28: North America Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027
Figure 29: North America Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027
Figure 30: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 31: Europe Nephropathic Cystinosis Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 32: Europe Nephropathic Cystinosis Treatment Market Attractiveness, by Country/sub-region, 2019–2027
Figure 33: Europe Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 34: Europe Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027
Figure 35: Europe Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 36: Europe Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027
Figure 37: Europe Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027
Figure 38: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 39: Asia Pacific Nephropathic Cystinosis Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 40: Asia Pacific Nephropathic Cystinosis Treatment Market Attractiveness, by Country/sub-region, 2019–2027
Figure 41: Asia Pacific Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 42: Asia Pacific Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027
Figure 43: Asia Pacific Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 44: Asia Pacific Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027
Figure 45: Asia Pacific Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027
Figure 46: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 47: Latin America Nephropathic Cystinosis Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 48: Latin America Nephropathic Cystinosis Treatment Market Attractiveness, by Country/sub-region, 2019–2027
Figure 49: Latin America Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 50: Latin America Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027
Figure 51: Latin America Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 52: Latin America Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027
Figure 53: Latin America Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027
Figure 54: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 55: Middle East & Africa Nephropathic Cystinosis Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 56: Middle East & Africa Nephropathic Cystinosis Treatment Market Attractiveness, by Country/sub-region, 2019–2027
Figure 57: Middle East & Africa Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 58: Middle East & Africa Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027
Figure 59: Middle East & Africa Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 60: Middle East & Africa Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027
Figure 61: Middle East & Africa Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027
Figure 62: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company
Figure 63: Horizon Therapeutics plc, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 64: Horizon Therapeutics plc, Breakdown of Pharmaceutical Division Net Sales, by Region, 2018
Figure 65: Horizon Therapeutics plc, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018
Figure 66: Horizon Therapeutics plc, Breakdown of Net Sales, by Business Segment, 2018
Figure 67: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 68: Mylan N.V. Breakdown of Net Sales, by Region, 2018
Figure 69: Mylan N.V. R&D Expenses (US$ Mn), 2017 and 2018
Figure 70: CHIESI Farmaceutici S.p.A., Breakdown of Net Sales (%), by Region, 2018
Figure 71: CHIESI Farmaceutici S.p.A., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 72: CHIESI Farmaceutici S.p.A., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 73: Recordati Group - Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 74: Recordati Group - R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 75: Recordati Group - Breakdown of Net Sales (%), by Region, 2018
